期刊
LEUKEMIA & LYMPHOMA
卷 60, 期 7, 页码 1758-1766出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2018.1542149
关键词
Allogeneic hematopoietic cell transplantation; post-transplant relapse; second allotransplant
资金
- National Cancer Institute [P01CA018029, P01CA078902]
- National Heart, Lung, and Blood Institute [P01HL122173]
- National Institutes of Health, Bethesda, MD
We analyzed outcomes of 126 patients with hematologic malignancies, who relapsed after first allogeneic hematopoietic cell transplantation (HCT) and received subsequent allografts. In 17 cases, the original donors were utilized, while in 109 cases different donors were identified. The 2-year overall survival (OS), relapse, and non-relapse mortality (NRM) rates were 33%, 42%, and 33%, respectively. Patients with early relapse after first allogeneic HCT (within 100 days vs. 100 days to 12 months vs. >12 months) had higher relapse rates (50% vs. 47% vs. 34%, respectively; p=.01) and worse OS (15% vs. 25% vs. 45%, respectively, p=.005) at 2 years after second allogeneic HCT. In conclusion, second allogeneic HCT should be considered in patients who relapse after first allografts, especially in those who relapse after more than a year. Utilizing a different donor for the second allotransplant including umbilical cord blood or HLA-haploidentical, related donors did not adversely impact outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据